T. Rowe Price Associates
NVO

T. Rowe Price Associates’s Novo Nordisk NVO Stock Holding History

T. Rowe Price Associates’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$561M Buy
11,704,719
+644,039
+6% +$27.7M 0.06% 260
2026
Q1 		$406M Buy
11,060,680
+1,372,418
+14% +$65M 0.05% 287
2025
Q4 		$493M Buy
9,688,262
+4,836,285
+100% +$247M 0.05% 270
2025
Q3 		$269M Sell
4,851,977
-1,351,287
-22% -$79.1M 0.03% 391
2025
Q2 		$428M Buy
6,203,264
+878,598
+17% +$59.8M 0.05% 295
2025
Q1 		$370M Sell
5,324,666
-1,020,452
-16% -$84.3M 0.05% 314
2024
Q4 		$546M Sell
6,345,118
-3,238,317
-34% -$350M 0.06% 254
2024
Q3 		$1.14B Buy
9,583,435
+79,671
+0.8% +$10.6M 0.13% 150
2024
Q2 		$1.36B Buy
9,503,764
+914,542
+11% +$121M 0.16% 124
2024
Q1 		$1.1B Buy
8,589,222
+823,036
+11% +$98M 0.14% 157
2023
Q4 		$803M Sell
7,766,186
-464,729
-6% -$46M 0.11% 183
2023
Q3 		$749M Buy
8,230,915
+576,025
+8% +$50.7M 0.11% 188
2023
Q2 		$619M Buy
7,654,890
+83,770
+1% +$6.84M 0.09% 221
2023
Q1 		$602M Buy
7,571,120
+7,102,208
+1,515% +$504M 0.09% 222
2022
Q4 		$31.7M Buy
+468,912
New +$27.5M 0.01% 793
2020
Q2 		– Sell
-713,596
Closed -$21.5M – 2528
2020
Q1 		$21.5M Buy
+713,596
New +$21.2M ﹤0.01% 1048

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

T. Rowe Price Associates's NVO Position: Q2 2026 in Review

T. Rowe Price Associates increased its Novo Nordisk (NVO) stake by 5.8% in Q2 2026, buying an estimated $27.7M and bringing the position to 11,704,719 shares worth $561M. The position accounts for 0.06% of the portfolio, ranked #260.

T. Rowe Price Associates first reported a position in NVO in Q1 2020 and has held it in 16 quarters since. The position peaked at $1.36B in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • T. Rowe Price Associates held 11,704,719 shares of Novo Nordisk worth $561M as of Q2 2026.
  • T. Rowe Price Associates bought 644,039 Novo Nordisk shares in Q2 2026, an estimated $27.7M.
  • Novo Nordisk made up 0.06% of T. Rowe Price Associates's portfolio in Q2 2026, its #260 holding.
  • T. Rowe Price Associates first reported a position in Novo Nordisk in Q1 2020 and has held it in 16 quarters since.
  • T. Rowe Price Associates's Novo Nordisk position peaked at $1.36B in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.